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Abstract
Background: Urea cycle disorders (UCDs) are rare inherited metabolic defects of ammonia detoxification. In about
half of patients presenting with a UCD, the first symptoms appear within a few days after birth. These neonatal
onset patients generally have a severe defect of urea cycle function and their survival and outcome prognoses are
often limited.
To understand better the current situation of neonatal onset in UCDs, we have performed a multicentre,
retrospective, non-interventional case series study focussing on the most severe UCDs, namely defects of carbamoyl
phosphate synthetase 1 (CPS1), ornithine transcarbamylase (OTC), and argininosuccinate synthetase (ASS).
Methods and results: Data of 63 patients were collected (27 patients with ASS deficiency, 23 patients with OTC
deficiency, and 12 patients with CPS1 deficiency, one patient definite diagnosis not documented). The majority of
patients (43/63, 68 %) had an initial ammonia concentration exceeding 500 μmol/L (normal < 100), of which most
(26/43, 60.5 %) were also encephalopathic and were treated with hemodialysis. In patients surviving the initial crisis,
recurrence of hyperammonemic events within the first 1.5 years of life occurred frequently (mean 3.6 events, range
0–20). Of all patients, 16 (25.4 %) died during or immediately after the neonatal period.
Conclusion: We observed in this cohort of neonatal onset UCD patients a high rate of initial life-threatening
hyperammonemia and a high risk of recurrence of severe hyperammonemic crises. These corresponded to a high
mortality rate during the entire study period (30.2 %) despite the fact that patients were treated in leading
European metabolic centers. This underlines the need to critically re-evaluate the current treatment strategies in
these patients.
Keywords: Urea cycle disorders, neonatal hyperammonemia, hyperammonemic crisis, Carbamoyl phosphate
synthetase 1 deficiency, Ornithine transcarbamylase deficiency, Argininosuccinate synthetase deficiency, Dialysis
Background
The urea cycle is the main pathway for detoxification of
nitrogenous waste products to urea and for arginine syn-
thesis in the human body. Urea cycle disorders (UCDs)
are due to enzyme or transporter defects in this meta-
bolic pathway. UCD patients are prone to metabolic de-
compensation with severe hyperammonemia, which can
result in brain edema and even death if treatment is ini-
tiated too late [1, 2]. UCDs are panethnic with an overall
incidence, including late onset forms, of about 1 in
35.000 [3] but this can vary in different populations [4].
The first presentation of a UCD can be at any age in life
and several different factors can trigger the metabolic
crisis [5, 6]. Approximately half of the patients present in
the first days of life after a short latent period [2, 7, 8]. In
these patients, the physiological catabolism of the new-
born is considered to trigger the decompensation. It is
reasonable to assume that especially severe UCDs with
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(almost) complete loss of function are prone to this early
onset. In contrast, patients with first symptoms beyond
the neonatal period are classified as late onset UCDs and
for these patients a variety of triggering factors are known,
mainly common febrile infections, protein loading, trauma
and other catabolic situations [9, 10].
In UCDs, insufficient detoxification of ammonia with
subsequent accumulation in the entire body but mainly
in the brain is the common pathophysiological mechan-
ism. Ammonia is a neurotoxic substance, which explains
why most clinical sequelae affect the central nervous
system [1, 11]. The mechanisms of neurotoxicity are not
entirely elucidated but it is clear that ammonia has sev-
eral deleterious effects on brain cells, including swelling
of astrocytes via glutamine accumulation, mitochondrial
dysfunction, and neurotransmitter dysbalance [12–15].
Ammonia neurotoxicity becomes irreversible after a
short interval (sometimes only few hours), especially if
ammonia concentrations are highly elevated [16]. The
duration of coma and the extent of ammonia elevation
are the most important prognostic factors for patients in
hyperammonemic crises [17, 18]. Although there are sin-
gle patients that survive such episodes, the prognosis
quoad vitam is commonly considered to be poor in
cases of an ammonia level ≥ 1000 μmol/L (reference
range ≤ 100 in newborns and ≤ 50 beyond the neonatal
period) and/or a duration of hyperammonemic crisis
of > 24 h [6].
Several studies describing cohorts treated before the
year 2000 report a poor overall prognosis for UCD pa-
tients [19, 20], especially those with a neonatal onset of
disease. However, the observations in these studies are
of limited value for counselling current patients and
families, as management modalities have improved.
More recent reports indicate improved patient outcome
with respect to the likelihood of survival for neonatal
onset patients [7, 21]. This improvement has been hy-
pothesized to be due to earlier diagnosis and better
treatments [7].
Since data on the current prognosis of neonatal onset
UCD patients are still scarce and often derived from
only small cohorts, we collected information on UCD
patients treated after the year 2001 in leading European
centers. We performed a multicentre, retrospective,
non-interventional case series study of neonatal onset
UCD patients with an observation period of up to five
years or until death. We focused on UCDs where the
presentation was more likely to be severe and in the
neonatal period: carbamoyl phosphate synthetase 1
(CPS1, OMIM *608307) deficiency (CPS1D, OMIM
#23730), ornithine transcarbamylase (OTC, OMIM
*300461) deficiency (OTCD, OMIM #311250, and argi-
ninosuccinate synthetase (ASS, OMIM *603470) defi-
ciency (ASSD, OMIM #215700). The aim of this study
was an improved understanding of the current situation
of neonatal onset UCD patients and to identify aspects
in the management of those patients that are relevant
for future studies.
Methods
Study population
To characterise the clinical course of neonatal onset
UCDs, we performed a multicentre, retrospective, non-
interventional study collecting data on patients affected
by symptomatic hyperammonemia in the neonatal
period and treated according to local protocols in the
years 2001 until 2013. Inclusion criteria were: neonatal
onset CPS1, OTC or ASS deficiencies with enzymatic or
molecular genetic confirmation, demographic data and
medical history, and data until death, orthotopic liver
transplantation (OLT), or at least six months of follow-
up. Exclusion criteria were: birth before 2001, severe
chronic or systemic disease other than UCD, and partici-
pation in the liver cell transplantation study SELICA
(Safety & Efficacy of Liver Cell Application, Cytonet,
Weinheim, Germany). The observation period of pa-
tients according to the study protocol was up to five
years or until death, but the analysis period was only
550 days. We decided for this shorter analysis period
since data was documented beyond 550 days in so few
cases, rendering analysis beyond this period uninforma-
tive. The decision for this shortened analysis period was
made before data evaluation.
Choice of study sites
Patients were included from eight metabolic tertiary
centres in five different European countries in order to
avoid bias resulting from single centre observations.
Study sites were chosen based on the presence of per-
manent senior metabolic specialists and on the availabil-
ity of written management protocols that were, however,
subject to local variability and may have changed during
the study period.
Data collection, ethics, consent and permissions
Study sites identified records from all UCD patients
treated in the years 2001 to 2013. Patients with CPS1,
OTC and ASS deficiencies were included if the observa-
tion period was at least six months or until death or
OLT. Documentation of the patients included informa-
tion on basic clinical and biochemical parameters,
hyperammonemic events (HE, defined as plasma ammo-
nia levels ≥ 150 μmol/L together with clinical symptoms
probably related to hyperammonemia), medication, diet,
and clinical outcome.
Parameters evaluated for this study included the number,
severity and duration of HEs, concentrations of plasma
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ammonia and glutamine levels, and, if applicable, age in
months at the time of death or at the time of OLT.
Primary endpoints were the time to the first HE after
the initial HE, the number and duration of HEs, and peak
plasma ammonia concentrations; events of increased
plasma glutamine (= “hyperglutaminemic events”), defined
as glutamine levels ≥ 1000 μmol/L (reference ranges for
glutamine varied between laboratories and are age-
dependent), time to the first hyperglutaminemic event,
and peak plasma glutamine concentrations; hospitaliza-
tions due to HE; survival for at least six months.
Secondary endpoints were details of medication and
other treatment modalities; time and outcome of OLT;
intake of protein.
Data collection was initiated after approval by the local
institutional review board was obtained. Since all data
collected in this study came from patient charts at sites,
and since this study was observational and non-
interventional in design and only anonymized data were
transferred to the sponsor, it was justified by the local
authorities not to obtain informed consent from patients
and parents. The only exception was in France where it
is a legal requirement to seek individual approval before
conducting any data processing.
Statistical analyses
Data were analysed as indicated using descriptive statis-
tics and Kaplan-Meier plots. A Microsoft Windows Ser-
ver 2003 operating system and several working stations
with Microsoft Windows XP Professional operating sys-
tem were used for data management and statistical ana-
lyses. SAS 9.2 and SAS 9.3 for Microsoft Windows were
the statistical packages in use. All programming of
tables, figures, listings, and statistical analyses were per-
formed using the statistical software package SAS® ver-
sions 9.2 and 9.3. After preparation of figures with SAS,
the graphical presentations were produced using alterna-
tive software packages (e.g. EXCEL).
Results
Study population and baseline characteristics
The individual retrospective observation and data collection
period in this study was until death, OLT, or at least
6 months (maximum five years) but the analysis period was
limited to 550 days. The first and last dates documented
were February 2001 and February 2013, respectively.
In total, 190 patients from the eight study centres were
assessed for eligibility. After exclusion of 127 patients
based on different reasons (reasons for exclusion of pa-
tients are given in Fig. 1), 63 patients remained as the
study population and were further analysed. The screen-
ing logs indicated that participating sites went thor-
oughly through their patient records and indeed
considered all patients potentially eligible for inclusion
into the study. Nevertheless, it cannot be excluded that
some patients were missed. Analysis of screening logs
further revealed that four patients who died early would
have been eligible for the study but were recorded only
on the screening log with no documentation in the
database.
Within the study population, the most frequent diag-
nosis was ASSD accounting for 27 of 63 patients
(42.8 %), followed by OTCD for 23 patients (36.5 %),
and CPS1D for 12 patients (19 %). In one patient, no
definite diagnosis was documented in the study records;
Fig. 1 Flow chart of screened patients with exclusion criteria and final size of study population. ASSD: Argininosuccinate synthetase deficiency,
ASLD: Argininosuccinate lyase deficiency, CPS1D: Carbamoyl phosphate synthetase 1 deficiency, HE: Hyperammonemic event, N: Number, OTCD:
Ornithine transcarbamylase deficiency, SELICA: Safety & Efficacy of Liver Cell Application, study on liver cell transplantation as treatment option for
severe metabolic disorders in patients with UCDs. *These patients would have been eligible for this study but were only recorded on the screening
log and not documented in the database
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nevertheless, to avoid data bias, this patient remained in-
cluded in this study (Table 1).
Out of the 23 OTC deficiency patients, 21 (91.3 %) were
male, resulting in a total of about 60 % male patients in-
cluded in the study, despite the fact that slightly more fe-
male than male patients were included with CPS1 and
ASS deficiencies (63.6 and 55.6 %, respectively).
Hyperammonemic events
During the initial metabolic crisis, the mean peak am-
monia concentration was 1378 μmol/L (SD 950 μmol/L,
range 161–4050) and the mean duration of the hyper-
ammonemic crisis was five days (range 1–19). Of all in-
cluded patients, 84.3 % experienced an initial ammonia
concentration > 500 μmol/L and the initial crisis lasted
for the majority of patients (n = 34; 66.7 %) two to seven
days. Nine patients did not experience an ammonia
level > 150 μmol/L as they were treated prospectively
based on family history and/or prenatal diagnosis (details
in Table 2).
Of the 43 patients with an initial HE > 500 μmol/L
(Table 2), the majority were encephalopathic and re-
quired dialysis (n = 26; 60.5 %). Within this group, al-
most all (42/43) were treated in parallel with infusions
of nitrogen scavengers and/or amino acids. Patients with
a less severe initial HE (ammonia 150–500 μmol/L)
rarely developed encephalopathy (only 1/8), and were
mainly treated with nitrogen scavengers alone (6/8) but
not with dialysis.
During the analysis period of a maximum of 550 days
or until OLT or death, after their initial metabolic crisis
patients suffered a mean of 3.6 HE (SD 4.8, range 0–20).
The mean peak plasma ammonia level during these HEs
was 539 μmol/L (SD 391, range 88–2060). Again, the
majority of these events (71.8 %) lasted for two to seven
days; whereby eight HEs (20.5 %) were limited to a single
day, and only three HEs (7.7 %) lasted > 8 days. HEs that
occurred after the initial crisis were generally less severe
(in terms of extent and duration of hyperammonemia)
than the first episode.
In 44 patients, HEs with ammonia levels ≥ 500 μmol/L
were recorded. Of those 44 patients, 26 patients survived
one (n = 20), two (n = 4), or three (n = 2) of the events. Of
the 18 patients who died during the HE or in the later
course of the study, 13 patients died immediately during
the first (n = 12) or second (n = 1) event. Only single pa-
tients had initially survived one (n = 3), three (n = 1), or four
(n = 1) episodes but died during later course of the study
(Table 3).
The likelihood of having a HE ≥ 500 μmol/L is high-
est in the first 28 days in all patient groups (Fig. 2a),
and an additional 37.2 % ± 6.2 % risk for a further cri-
sis until day 550. Patients with OTCD and CPS1D
suffer these HEs earlier and with a higher probability
in the first 25 days than patients with ASSD (Fig. 2b).
When the incidences of HEs were calculated per
30 days, there was a significant difference between
the OTCD or CPS1D and ASSD groups (U-test
OTCD versus ASSD: p = 0.0117 and CPS1D versus
ASSD: p = 0.0388) but not between the proximal
UCDs (U-test OTCD versus CPS1D: p = 0.7176). 13
patients had their first HE during the neonatal period
with ammonia > 500 μmol/L, but no further HEs for
at least 180 days; one additional patient, diagnosed
through positive family history and early treated, did
not have an initial ammonia level > 500 μmol/L and
no further HE for 180 days (Fig. 2a, b).
Plasma glutamine concentrations
Plasma glutamine was recorded through the study from
a total of 58 patients, as values from five patients were
missing. Patients suffered a mean of 2.7 ± 3.7 (range 0–
19) events with glutamine concentrations ≥ 1000 μmol/L
(reference ranges for glutamine varied between labora-
tories and are age-dependent; the upper limit of normal
is between 746 and 798 μmol/L according to [22]) over
the analysis period. The mean peak glutamine level was
1400 ± 662 μmol/L (range 680–5428). The hyperglutami-
nemic events lasted in 26 patients (48.1 %) two to seven
days, in 21 patients (38.9 %) eight to 14 days, and in
seven patients (13 %) only a single day. Unfortunately, as
only the date but not the exact time of blood sampling
was documented, it was not possible to draw safe con-
clusions by comparing the time course of elevations of
plasma glutamine (or ammonia) and outcome.
Table 1 Baseline characteristics of the study population, diagnosis and gender
CPS1D OTCD ASSD Study population
Patients 12 23 27 63a
Gender
male 4 (36.4 %) 21 (91.3 %) 12 (44.4 %) 37 (59.7 %)
female 7 (63.6 %) 2 (8.7 %) 15 (55.6 %) 25 (40.3 %)
no gender recorded 1 1
ASSD Argininosuccinate synthetase deficiency, CPS1D Carbamoyl phosphate synthetase 1 deficiency, OTCD Ornithine transcarbamylase deficiency
aone patient missing the documentation of the diagnosis
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Medication at onset of disease
In 51 patients (81 %), use of ammonia-lowering medi-
cation was documented during the initial presentation
after the diagnosis of acute hyperammonemia was
made. The majority of patients received infusions of
L-arginine (68.3 %) and sodium benzoate (65.1 %).
Other drugs were given less often, e.g. the combin-
ation of sodium phenylacetate and sodium benzoate
in only 4 patients (6.3 %). A summary of all drugs
given during the initial presentation is shown in
Table 4.
Orthotopic liver transplantation and intake of protein
In our study population, 11 of the 51 patients surviving
the neonatal period and first HE underwent OLT. Most
transplantations were performed in patients with OTCD
(5 of 14 OTCD patients surviving the neonatal period);
two patients with CPS1D underwent OLT (2 of 9 CPS1D
patients surviving the neonatal period), and four patients
with ASSD (4 of 27 ASSD patients surviving the neo-
natal period). The indication for OLT was not recorded
in this study.
Age at OLT varied widely from a minimum of 116 days
to a maximum of 1663 days (mean 453 days). There was
a trend that patients with OTCD were transplanted earl-
ier if compared to patients with CPS1D and ASSD
(Fig. 3).
The intake of protein in g/kg bodyweight (BW) was
documented in 55 patients (26 ASSD, 19 OTCD, 10
CPS1D). In all, the intake of protein during the analysis
period was restricted to 1.11 ± 0.38 g/kg BW (mean ±
SD) with only marginal differences between groups:
ASSD 1.25 ± 0.31, OTCD 0.99 ± 0.44, CPS1D 0.94 ± 0.35.
However, the difference between the diagnosis groups
with the highest (ASSD) and lowest (CPS1D) protein
Table 2 Characteristics of initial hyperammonemic episodes in all patients
CPS1D OTCD ASSD All patients
Number of patients 12 23 27 63
First hyperammonemic crisis≥ 150 μmol/L N = 20a N = 60a
No – 3 (15.0 %) 6 (22.2 %) 9 (15.0 %)
Yes 12 (100.0 %) 17 (85.0 %) 21 (77.8 %) 51 (85.0 %)
Peak concentration [μmol/L]
Minimum 203 385 161 161
Maximum 2627 4050 2690 4050
Mean 1257 1875 1084 1378
SD 929 1105 682 950
150 – < 250 1 (8.3 %) – 1 (4.8 %) 2 (3.9 %)
250 – < 500 2 (16.7 %) 1 (5.9 %) 3 (14.3 %) 6 (11.8 %)
≥ 500 9 (75.0 %) 16 (94.1 %) 17 (81.0 %) 43 (84.3 %)
Duration of crisis
1 day – 3 (17.6 %) 3 (14.3 %) 6 (11.8 %)
2–7 days 8 (66.7 %) 9 (52.9 %) 16 (76.2 %) 34 (66.7 %)
8–14 days 3 (25.0 %) 4 (23.5 %) 2 (9.5 %) 9 (17.6 %)
15–19 days 1 (8.3 %) 1 (5.9 %) – 2 (3.9 %)
Peak concentration of ammonia is the highest level of plasma ammonia during the initial crisis. SD Standard deviation
athree missing values
Table 3 Incidences of hyperammonemic events with a peak
ammonia ≥ 500 μmol/L, maximum analysis period 550 days
Parameter CPS1D OTCD ASSD All
patients
Number of patients 12 23 27 63
Type of hyperammonemic event
▪ no event≥ 500 μmol/L 3 6 10 19
▪ at least one event≥ 500 μmol/L,
patient alive
5 7 13 26
individual number of events≥ 500 μmol/L
1 3 6 10 20
2 1 1 2 4
3 1 – 1 2
▪ at least one event≥ 500 μmol/L,
patient died
4 10 4 18
individual number of events≥ 500 μmol/L
1 4 9 2 15
2 – 1 – 1
3 – – 1 1
4 – – 1 1
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intake did not reach statistical significance (Kruskal
Wallis test: p = 0.0570).
Survival
Within the total study population of 63 patients, twelve
patients (19 %) died during the initial crisis, and another
four patients died within two weeks after the end of
their first crisis (as already stated above, another four pa-
tients who died during their initial crisis would have also
been eligible but are not included here). Thus, 16 pa-
tients (25.4 %) died during or immediately after the neo-
natal period. Patients with OTCD had the highest
mortality rate (10 of 23 patients) followed by patients
with CPS1D (4 of 12 patients), while patients with ASSD
had lower mortality in this study (4 of 27 patients).
Two further deaths in patients with ASSD were re-
ported later than 1.5 years. Thus, 28.6 % of all patients
died during the total study period of five years. In
addition, one patient died one day after OLT. Thus in
total, 19 of the 63 patients (30.2 %) died during the
observation period of five years.
Study termination
In about half of the patients (n = 33; 52.4 % of total),
data collection for the entire planned observation period
of at least 6 months was feasible. The main reason for
an early study termination was death, which occurred in
18 patients (28.6 % of total). Eleven patients (17.5 % of
total) received an OLT and were only studied until this
intervention. One patient was treated with liver cell
Fig. 2 a Kaplan Meier plot of the time (shown in days of life of the patients) to first occurrence of ammonia≥ 500 μmol/L during or after the
initial crisis in all patients. This figure includes all 12 patients that died during the initial crisis. b Kaplan Maier plot of the time (shown in days of
life of the patients) to first occurrence of ammonia≥ 500 μmol/L, separated by the three groups of patients (ASSD, CPS1D, OTCD)
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infusion and was therefore removed from further ana-
lysis. Table 5 gives details of the reasons for study
termination.
Discussion
This was a European multicentre, retrospective, non-
interventional case series reporting the natural course of
neonatal onset UCD patients treated with standard care
within the first five years of life. Data evaluation focussed
on the basic clinical course and outcome, and on plasma
levels of ammonia and glutamine at manifestation and
during the course of the study. Our study is the largest
of its kind in recent years in Europe, describing the nat-
ural course of 63 UCD patients treated in eight meta-
bolic centres in Austria, France, Germany, Italy and
Switzerland according to local management standards.
Study population
There are only few case series describing the natural
course after neonatal onset in UCD patients and reports
from previous decades often differ in the overall man-
agement from current practice [17, 20, 23]. It is
Table 4 Medication given during the initial crisis
CPS1D OTCD ASSD All patients
Number of patients 12 23 27 63
Medication during initial crisis
unclear – 5 (21.7 %) 7 (25.9 %) 12 (19.0 %)
yes 12 (100 %) 18 (78.3 %) 20 (74.1 %) 51 (81.0 %)
L-arginine 8 (66.7 %) 15 (65.2 %) 20 (74.1 %) 43 (68.3 %)
Benzoic acid 1 (8.3 %) – – 1 (1.6 %)
Carglumic acid 1 (8.3 %) 3 (13.0 %) 2 (7.4 %) 6 (9.5 %)
L-citrulline 1 (8.3 %) 2 (8.7 %) – 3 (4.8 %)
Levocarnitine 3 (25.0 %) 7 (30.4 %) 8 (29.6 %) 18 (28.6 %)
Sodium benzoate 7 (58.3 %) 15 (65.2 %) 18 (66.7 %) 41 (65.1 %)
Sodium phenylacetate & sodium benzoate – 2 (8.7 %) 2 (7.4 %) 4 (6.3 %)
Sodium phenylbutyrate 1 (8.3 %) 4 (17.4 %) 7 (25.9 %) 12 (19.0 %)
Unclear means patients have not received medication or data were not entered
Fig. 3 Kaplan-Meier plot of the time (shown in days of life of the patients) to orthotopic liver transplantation (OLT), separated by the three groups of
patients (ASSD, CPS1D, OTCD)
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important to state that the present case series study is in
line with current literature and thus comparable to other
neonatal onset UCD patient series in terms of epidemi-
ology, because ASSD was the most frequent UCD,
followed by OTCD and CPS1D [24–26]; in some other
reports however, OTCD was more frequent than ASSD
[7, 9]. Nevertheless, the higher numbers of ASSD
patients in our cohort is not in contrast to the undispu-
table higher incidence of OTCD as this study only in-
cludes patients with neonatal onset.
Of 190 patients screened, 63 were included in the
study in accordance with the inclusion criteria. Four pa-
tients could not be included in this study, although pa-
tients would have been eligible, since the participating
center did not report data. This failure to include the
four patients obviously results in a bias as these patients
would have increased the mortality in the early phase, or
maybe even in the neonatal period.
Survival
The mortality rate during the entire study period was
30.2 %, similar to a recent metaanalysis reporting sur-
vival of the neonatal period for 40–81 % of patients with
neonatal onset UCDs, depending on their underlying de-
fect [27]. In our study, OTCD patients had the highest
death rate (43.4 %), followed by CPS1D (36.4 %) and
ASSD (14.8 %). This observation is similar to more re-
cent reports from large cohorts in the United States
(US), which found mortality of neonatal onset UCD pa-
tients to be 24 % [25] and 32 % [21]. The survival data
from this study are better than from reports describing
patients before the year 2000, where 5-year survival rates
were 22 % in patients treated before 1995 [19], 35 % in a
cohort that was treated between 1975 and 1986 [20],
and only 16 % in a study with 121 neonatal onset UCD
patients from 1972 to 2000 [2]. In contrast, a very recent
study from a multi-center investigation in the US re-
ported a mortality rate for neonatal onset UCD patients
of only 4 %, even though the size of the cohort as well
as the study period were similar to the present study
[26]. However, the authors mention an additional nine
deceased patients that were only diagnosed postmortem
and who were not enrolled in their study (which then
would have resulted in a mortality rate of 11.6 %). Al-
though by itself this only partly explains the surprisingly
low mortality rate found in this study, it also points to-
wards underreporting or sampling bias as key factors for
the low rate found. Another study reporting neonatal
onset UCD patients treated in the same time period in
different centers in Japan also had a low mortality rate,
17 %. However, the lower mortality rate in this case may
have been due to the inclusion of all UCDs [7].
It should be noted that newborn screening (NBS) for
ASSD was not in place in any of the countries involved
in this study. NBS may have an impact on the survival
and outcome of UCD patients [28], a conclusion sup-
ported by data from the European registry, where a
trend towards improved long-term neurological out-
come has been found for patients with ASSD identified
by NBS [29].
Hyperammonemic events, dialysis and encephalopathy
Hemodialysis is currently the most effective way of am-
monia detoxification. It is the therapy of choice if plasma
ammonia levels exceed 500 μmol/L or if other measures
fail to lower the ammonia concentration [6]. In line with
this, 36 patients with ammonia levels > 500 μmol/L dur-
ing their initial metabolic crisis received dialysis and 26
of them were in encephalopathy before dialysis was initi-
ated. In addition, four further patients with ammonia
levels > 500 μmol/L were encephalopathic during their
initial metabolic crisis but did not receive dialysis. This
high rate of encephalopathic patients during the first HE
requiring dialysis (48 % of all patients in this study) is in
line with data from Japanese centers where 59/151
(39 %) of patients were treated with dialysis during their
first hyperammonemic attack (characterized by a mean peak
ammonia level at onset of dialysis of 856 μmol/L) [7]. Coma
is a known predictor of poor outcome [17, 18], and the vast
majority of patients with an initial HE > 360 μmol/L had a
poor prognosis in terms of neurodevelopmental outcome
and survival despite receiving hemodialysis [7]. Thus, al-
though our study does not provide data on neurocognitive
outcome, the high ammonia levels and mortality rate in our
cohort underline the need to re-evaluate current treatment
strategies, including the threshold to start extracorporeal
Table 5 Reason for study termination
Reason for study termination CPS1D OTCD ASSD All patients
Number of patients 12 23 27 63a
Death 4 (33.3 %) 10 (43.5 %) 4 (14.8 %) 18 (28.6 %)
Liver cell infusion – 1 (4.3 %) – 1 (1.6 %)
Orthotopic liver transplantation (OLT) 2# (16.7 %) 5 (21.7 %) 4 (14.8 %) 11 (17.5 %)
Study end 6 (50.0 %) 7 (30.4 %) 19 (70.4 %) 33 a (52.4 %)
OLT Orthotopic liver transplantation
aone missing diagnosis; # one CPS1D patient died early after OLT and the cause of study termination in this patient is thus OLT
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detoxification if ammonia levels exceed 500 μmol/L [6]. Be-
cause of the poor outcome in their study, Japanese authors
concluded that patients with a “peak ammonia level greater
than 180 μmol/l at the onset should receive hemodialysis”
[7]. Such more aggressive treatment, at least of neonatal
hyperammonemia exceeding 300 μmol/L, was already re-
ported from the US where 60 % of neonatal hyperammone-
mic episodes, in which 50 % of neonates were “comatose”,
were treated with some form of dialysis (including various
methods of hemodialysis or hemo(dia)filtration, and peri-
toneal dialysis) [21].
Hyperammonemic events and glutamine concentrations
Since glutamine is generally considered to be a predictor
of hyperammonemic crises and of poor neurocognitive
outcome [25, 30], we included this parameter in our
analysis. We used as definition for significant hyperglu-
taminemia a plasma concentration of > 1000 μmol/L
(reference ranges are age-dependent and varied slightly
between study sites). During the analysis period of up to
550 days, patients suffered a mean of 2.7 episodes with a
glutamine level above this limit.
Medication at onset
Drug treatment of UCD patients always consists of a
combination of nitrogen scavengers with arginine or cit-
rulline. Depending on the specific defect, but also de-
pending on different approaches in different countries,
the details of therapy vary between centers. Despite be-
ing in use for many decades, it is still unclear whether
there is a relevant difference in efficacy between these
various protocols. Attempts to harmonize treatment
strategies have resulted in suggested guidelines, which
were based on a thorough evaluation of the literature
but which were not yet in place for the patients of this
study [6]. Thus, most patients in this study were treated
with different medications during their metabolic crises.
The most frequently used medications at onset were L-
arginine (used in 68 % of patients) and sodium benzoate
(used in 65 % of patients), followed by sodium phenylbu-
tyrate or phenylacetate (used in 25 % of patients). This
also reflects differences in the practice of European cen-
ters compared to those in the US, where sodium benzo-
ate and L-arginine were only used in 5 % and 23 % of
patients, respectively. Instead, the preferred initial medi-
cations in the American centers were sodium phenylbu-
tyrate (used in 37 % of patients) and citrulline (used in
31 % of patients) [24]. The current “European” approach
seems to be more in line with practices in Japan, where
the majority of patients suffering from a HE received L-
arginine together with sodium benzoate (e.g. used for
72 % of OTCD cases, 61 % of CPS1D cases, and 79 % of
ASSD cases) [7]. This difference in the management of
these most vulnerable patients, those affected by life-
threatening hyperammonemia, should be seen as a
chance to compare treatment approaches, something
that is probably best achieved in data mining projects of
the large US and European (and maybe also Japanese)
UCD registries [31, 32].
Orthotopic liver transplantation
Definitive treatment of the underlying UCD using OLT
was performed in 11 patients (17.5 % of the study popu-
lation; 5 OTCD, 4 ASSD, and 2 CPS1D patients). Except
for two patients, this procedure was performed in the
first 550 days of the study period, which likely reflects
the early decision in favor of OLT although this definite
treatment was done relatively late in some of the pa-
tients (mean 453 days, range 116–663). The time point
of OLT in our study is in agreement with data from the
US registry, which reports OLT in 42/66 patients before
2 years of age [25]. However, the number of patients re-
ceiving OLT in this study is lower than in another study
from the US that reports liver transplantation in 66 % of
CPS1D and OTCD patients [26]. A similar proportion of
UCD patients (24 %) received liver transplantation in
Japan [7]. In our cohort, one patient died one day after
OLT from multiorgan failure but the numbers are too
low to be compared with mortality data from other
(larger) studies (in a study from Japan, one patient from
a total 42 patients died of complications after the
procedure [7]).
Conclusion
This study provides data on the clinical course of 63
UCD patients with a neonatal onset of disease. The mor-
tality rate during the entire study period of 30.2 % is
higher than reported before in other recent case series.
A possible explanation for this may be underreporting of
severe cases in other studies. The data from this retro-
spective study confirm the high risk of neonatal onset
UCD patients not only for an initial life-threatening de-
compensation but also for recurrent hyperammonemic
crises, which may likewise result in permanent neuro-
logical damage. We therefore conclude that novel thera-
peutic approaches are still highly needed for this group
of patients. Until these are effectively in place, current
treatment protocols, which recommend start of extra-
corporeal detoxification if ammonia levels exceed
500 μmol/L, should be re-evaluated since earlier start of
dialysis may be beneficial. In addition, the high risk of
recurrent hyperammonemic crisis underlines recom-
mendations to perform early liver transplantation as
long as this remains the only curative approach for neo-
natal onset UCD patients. Finally, future studies should
be planned to determine whether current patients have
better outcomes than reported in this historical cohort.
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